Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
Zacks Investment Research on MSN2d
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock UpNektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...
Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...
2d
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...
EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...
NEKTAR THERAPEUTICS ($NKTR) posted quarterly earnings results on Wednesday, March 12th. The company reported earnings of $0.15 per share, beating estimates of -$0.17 ...
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...
Nektar Therapeutics (NKTR) reported $29.18 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 22.1%. EPS of -$0.15 for the same period compares to -$ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback